NCT01428154View on ClinicalTrials.gov

Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

April 30, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions

AnemiaChronic Kidney Disease

Interventions

DRUG

Darbepoetin alfa

A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY